🪞 Larry Robbins · Glenview
Long-short healthcare.
Build a basket from the top picks →
🔮 Predicted next buys: quarter ending 2026-06-30
Pure model output for Larry Robbins · Glenview’s next 13F filing, no public confirmation yet. Probabilities are the model’s raw scores.
| # | Ticker | Company | Model probability |
|---|---|---|---|
| 1 | AKAM | Akamai Technologies Inc | 93% |
| 2 | CSCO | Cisco Systems Inc | 93% |
| 3 | BKR | Baker Hughes Co | 92% |
| 4 | PRMB | Primo Brands Corp | 91% |
| 5 | IYR | Ishares Us Real Estate Etf | 89% |
| 6 | ELF | Elf Beauty Inc | 87% |
| 7 | NDQ | Invesco Qqq Trust Series 1 | 81% |
| 8 | FUTU | Futu Holdings Ltd-Adr | 81% |
| 9 | EMB | Ishares Jp Morgan Usd Emergi | 77% |
| 10 | DYH | Target Corp | 77% |
📉 Predicted exits, conviction fading
Of Larry Robbins · Glenview’s current disclosed holdings, the names a model flags as most likely to be EXITED or TRIMMED next quarter, before the 13F shows it. Model score (not a calibrated probability), ranked. Holdings as of 2026-03-31.
| Ticker | Company | Weight | Last move | Sell likelihood |
|---|---|---|---|---|
| BIIB | Biogen Inc | 0.26% | trimmed last Q | ▲▲▲ 71 |
| DOCN | Digitalocean Hldgs Inc | 0.54% | trimmed last Q | ▲▲▲ 70 |
| ONTO | Onto Innovation Inc | 1.54% | trimmed last Q | ▲▲ 67 |
| - | Lionsgate Studios Corp | 0.67% | trimmed last Q | ▲▲ 66 |
| TECH | Bio-Techne Corp | 0.24% | trimmed last Q | ▲▲ 65 |
| Z | Zillow Group Inc | 0.82% | trimmed last Q | ▲▲ 64 |
| SGRY | Surgery Partners Inc | 0.54% | trimmed last Q | ▲▲ 64 |
| IWM | Ishares Tr | 2.33% | trimmed last Q | ▲▲ 64 |
⚠️ This predicts the ACTION (whether Larry Robbins · Glenview reduces the position), not a return and not a short. A 13F shows long positions only, so a “sell” here means exiting or cutting a long, never shorting the stock. Walk-forward validated on the decision (AUC ≈ 0.66), but acting on it is not shown to make money. Research, not advice.
📜 Top disclosed holdings: Mar 2026
| Ticker | Company | Weight | Last change |
|---|---|---|---|
| CVS | Cvs Health Corp | 14.78% | ✊ Held |
| GPN | Global Pmts Inc | 10.91% | ✊ Held |
| THC | Tenet Healthcare Corp | 7.22% | ➖ Trimmed |
| AMZN | Amazon Com Inc | 5.54% | ➕ Added |
| TEVA | Teva Pharmaceutical Inds Ltd | 5.04% | ➖ Trimmed |
| NDQ | Invesco Qqq Tr | 4.76% | 🆕 New |
| CI | The Cigna Group | 3.34% | ➕ Added |
| AMD | Advanced Micro Devices Inc | 3.32% | ➕ Added |
| TMO | Thermo Fisher Scientific Inc | 3.09% | ➕ Added |
| VTRS | Viatris Inc | 3.08% | ➖ Trimmed |
| DXC | Dxc Technology Co | 2.81% | ✊ Held |
| CNC | Centene Corp Del | 2.64% | ➕ Added |
| UBER | Uber Technologies Inc | 2.63% | ➕ Added |
| GTM | Zoominfo Technologies Inc | 2.39% | ➖ Trimmed |
| IWM | Ishares Tr | 2.33% | ➖ Trimmed |
Source: SEC Form 13F (public domain), long U.S. equity positions only, disclosed up to 45 days after quarter-end. Top 15 of 43 shown.
💲 Where they bought: accumulation cost
13F shows holdings, not trade prices. Implied average cost is total value ÷ shares; the zone is the price range that quarter, where they accumulated. “vs cost” is today versus that average. This is where they bought, not a future price.
| Ticker | Avg cost | Accumulation zone | Today | vs cost |
|---|---|---|---|---|
| CVS | $71.82 | $69–$83 | $107.47 | +49.6% |
| GPN | $67.30 | $66–$82 | $77.82 | +15.6% |
| THC | $188.71 | $188–$245 | $183.69 | -2.7% |
| AMZN | $208.27 | $199–$247 | $247.23 | +18.7% |
| TEVA | $30.12 | $28–$36 | $32.03 | +6.3% |
| CI | $266.75 | $257–$291 | $303.35 | +13.7% |
| AMD | $203.43 | $191–$260 | $500.94 | +146.2% |
| TMO | $491.53 | $464–$638 | $543.19 | +10.5% |
| VTRS | $13.51 | $12–$16 | $16.80 | +24.4% |
| DXC | $12.57 | $12–$15 | $9.26 | -26.3% |
🎯 Disclosed options: calls vs puts
13F discloses option positions too. Calls lean bullish or levered; puts lean bearish or hedging. This is the not-just-buying side of what they disclose.
| Ticker | Position | Lean |
|---|---|---|
| NDQ | calls | bullish / levered |
| IWM | puts | bearish / hedge |
| GPN | calls | bullish / levered |
Source: 13F option lines (put_call). Disclosed positions, not advice.
🧬 Factor fingerprint, the style behind the book
66% of Larry Robbins · Glenview’s day-to-day swings are explained by public, buyable factors (Fama-French 5 + momentum), regressed on their current disclosed book (14 of 15 names, ~451 trading days). Market beta 0.93.
⚠️ This is the part the great investors can’t hide: their style is a tilt toward known factors, and every one of these is sold as a cheap index ETF. Buying the factors gets you most of the book for a few basis points. What’s left after the factors (the residual) is noisy on a single concentrated book and is not a reliable edge, read this as transparency about the style you’re copying, not a secret signal. Loadings are in-sample on current static weights, U.S. long positions only. Research, not advice.
📈 This mirror’s track: backtest vs S&P 500
⚠️ Read this honestly. Leak-free walk-forward backtest: top-10 predicted new buys ranked from a broad ~2,000-name universe known at the rebalance date, equal-weight, 1-quarter holds, complete quarters only, gross (before costs). Small samples, per-investor edges are noisy and not statistically significant. The consensus mirror's backtest shows +1.8 pts/quarter net vs the S&P 500 over 47 complete quarters (2014–2026), directional, NOT statistically significant (t≈1.4; 95% CI includes zero). Past performance does not predict future results. Not investment advice.
🔔 Follow this mirror
New filings and predicted-buy refreshes are published to every reader at once, weekly digest (email) · build a basket.
Prior Moves is a research publication: one impersonal model portfolio per investor, identical for every reader. You place any trades yourself at your own broker. No execution, no custody, no individualised advice.